STOK

USD

Stoke Therapeutics Inc. Common Stock

$25.340+0.340 (1.360%)

Цена в режиме реального времени

Healthcare

Биотехнология

Соединенные Штаты

График цен

Loading Chart...

Ключевые показатели

Рыночные показатели

Фундаментальные показатели компании

Статистические данные торговли

Рыночные показатели

Открытие

$25.000

Максимум

$25.550

Минимум

$24.660

Объем

0.81M

Фундаментальные показатели компании

Рыночная капитализация

1.4B

Отрасль

Биотехнология

Страна

United States

Статистические данные торговли

Средний объем

1.17M

Биржа

NMS

Валюта

USD

52-недельный диапазон

Минимум $5.35Текущая $25.340Максимум $38.693

Отчет об анализе ИИ

Последнее обновление: 30 окт. 2025 г.

Сгенерировано ИИИсточник данных: Yahoo Finance, Bloomberg, SEC

Stoke Therapeutics (STOK): Riding Wave of Biotech Optimism, But Risks Lurk

Price Action: Volatility With Clear Upside Momentum

The stock has swung between $12.40 and $38.69 over the past 90 days, reflecting high sensitivity to news. Key patterns:

Explosive breakout in October (up 34% from $20.68 to $27.31 in 4 days, then a dramatic spike to $38.69 on Oct 16)
Recent correction (-4.3% from Oct 22 to 29) followed by a small rebound on Oct 30 (closing at $31.66 vs. $31.41 open)
Volume surged to 4x average during the October rally, showing strong institutional interest

News Impact: Positive Clinical Data Drives Surge

Three catalysts fueled the October rally:

Связанные новости

5 нояб. 2025 г. · 10:15

Analyst Upgrades

BTIG Reiterates Buy on Stoke Therapeutics, Maintains $39 Price Target

BTIG analyst Thomas Shrader reiterates Stoke Therapeutics with a Buy and maintains $39 price target.

Просмотреть больше

BTIG Reiterates Buy on Stoke Therapeutics, Maintains $39 Price Target

3 нояб. 2025 г. · 15:53

Analyst Upgrades

JP Morgan Maintains Neutral on Stoke Therapeutics, Raises Price Target to $25

JP Morgan analyst Jessica Fye maintains Stoke Therapeutics with a Neutral and raises the price target from $15 to $25.

Просмотреть больше

JP Morgan Maintains Neutral on Stoke Therapeutics, Raises Price Target to $25

30 окт. 2025 г. · 20:30

BusinessWire

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates

Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in

Просмотреть больше